Total Funding
69
60
Total FundingSeries A raised
Growth Score
-6 pts
Heat Score
-17 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
15168
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Uri Laserson: Scientific FounderPast Role: Icahn School of Medicine at Mount Sinai, Assistant Professor- Jane Osbourn: CEO, Co-Founder
About the Company
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
The company is building their transformative engine to identify drug targets and develop a pipeline of antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
Alchemab
Therapeutics was established in 2019 by Uri Laserson and Jane Osbourn in London, England.
